BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrology Dialysis Transplantation 2006;22:309-12. [DOI: 10.1093/ndt/gfl824] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Shroff R, Ledermann S. Long-term outcome of chronic dialysis in children. Pediatr Nephrol 2009;24:463-74. [PMID: 18214549 DOI: 10.1007/s00467-007-0700-2] [Cited by in Crossref: 59] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
2 Ingelfinger JR. Through the Looking Glass: Anemia Guidelines, Vested Interests, and Distortions. CJASN 2007;2:415-7. [DOI: 10.2215/cjn.01340307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
3 Fort J, Cuevas X, Garcia F, Perez-garcia R, Llados F, Lozano J, Martin-malo A; on behalf of all investigators from the ANSWER study. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrology Dialysis Transplantation 2010;25:2702-10. [DOI: 10.1093/ndt/gfq073] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
4 Singh AK. Anemia of chronic kidney disease: CHOIR and the FDA. Nat Rev Nephrol 2007;3:406-7. [DOI: 10.1038/ncpneph0539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
5 Pfeffer MA. Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo. Am J Kidney Dis 2008;51:366-9. [PMID: 18295051 DOI: 10.1053/j.ajkd.2008.01.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
6 Lacson E Jr, Wang W, Hakim RM, Teng M, Lazarus JM. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis 2009;53:79-90. [PMID: 18930570 DOI: 10.1053/j.ajkd.2008.07.031] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 5.9] [Reference Citation Analysis]
7 Szczech L. Anemia trials: lessons for clinicians, politicians, and third-party payers. Kidney International 2010;77:479-80. [DOI: 10.1038/ki.2009.496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
9 Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SD, Knusel B, Sun Y, Wasserman SM, van Veldhuisen DJ. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure 2009;11:1071-7. [DOI: 10.1093/eurjhf/hfp130] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
10 Portolés JM, de Francisco AL, Górriz JL, Martínez-Castelao A, López-Gómez JM, Arias M, de la Cruz JJ, Cases A, Fernández E, Aljama P. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. Kidney Int Suppl 2008;:S82-7. [PMID: 19034334 DOI: 10.1038/ki.2008.524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
11 de Francisco AL. Individualizing anaemia therapy. NDT Plus 2010;3:519-26. [PMID: 25949459 DOI: 10.1093/ndtplus/sfq164] [Reference Citation Analysis]
12 Levin A. Management of anemia with intravenous methoxy polyethylene glycol–epoetin beta in patients on dialysis. Nat Rev Nephrol 2008;4:186-7. [DOI: 10.1038/ncpneph0761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Macdougall IC, Tomson CR, Steenkamp M, Ansell D. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up. Nephrol Dial Transplant 2010;25:914-9. [PMID: 19934090 DOI: 10.1093/ndt/gfp550] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
14 Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M, Nuti R. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007;154:645.e9-15. [PMID: 17892986 DOI: 10.1016/j.ahj.2007.07.022] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 5.8] [Reference Citation Analysis]
15 Sonmez A, Yilmaz MI, Saglam M, Kilic S, Eyileten T, Uckaya G, Caglar K, Oguz Y, Vural A, Yenicesu M, Kutlu M, Kinalp C, Zoccali C. The relationship between hemoglobin levels and endothelial functions in diabetes mellitus. Clin J Am Soc Nephrol 2010;5:45-50. [PMID: 19833907 DOI: 10.2215/CJN.05080709] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
16 Berns JS, Fishbane S. Summary and Comment: CHOIR, CREATE, and Anemia Treatment in Patients with CKD: ANEMIA TREATMENT IN PATIENTS WITH CKD. Seminars in Dialysis 2007;20:277-9. [DOI: 10.1111/j.1525-139x.2007.00290.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Goldsmith D, Covic A. Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrology Dialysis Transplantation 2010;25:1734-7. [DOI: 10.1093/ndt/gfq099] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
18 Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients- a critical review. Semin Dial 2008;21:1-6. [PMID: 18251947 DOI: 10.1111/j.1525-139X.2007.00329.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Singh AK. Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro. JASN 2009;20:1436-43. [DOI: 10.1681/asn.2009040444] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52:501-511. [PMID: 18687241 DOI: 10.1016/j.jacc.2008.04.044] [Cited by in Crossref: 195] [Cited by in F6Publishing: 162] [Article Influence: 13.9] [Reference Citation Analysis]
21 Andreucci M, Fuiano G, Presta P, Lucisano G, Leone F, Fuiano L, Bisesti V, Esposito P, Russo D, Memoli B. Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Prolif. 2009;42:554-561. [PMID: 19508320 DOI: 10.1111/j.1365-2184.2009.00617.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
22 Song HY, Wei CM, Zhou WX, Hu HF, Wan QJ. Association between admission hemoglobin level and prognosis in patients with type 2 diabetes mellitus. World J Diabetes 2021; 12(11): 1917-1927 [PMID: 34888016 DOI: 10.4239/wjd.v12.i11.1917] [Reference Citation Analysis]
23 Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrology Dialysis Transplantation 2008;23:2879-83. [DOI: 10.1093/ndt/gfn109] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
24 Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H; TREAT Investigators. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2009;54:59-69. [PMID: 19501439 DOI: 10.1053/j.ajkd.2009.04.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
25 Liu WS, Chu DC, Chan HL, Li SY, Liu CK, Yang CY, Chen YW, Lee PC, Lai YT, Lin CC. Fixed dose of long-acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis. Clin Exp Pharmacol Physiol 2016;43:875-82. [PMID: 27385380 DOI: 10.1111/1440-1681.12618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Souza E, Cho KH, Harris ST, Flindt NR, Watt RK, Pai AB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease? Expert Opin Investig Drugs 2020;29:831-44. [PMID: 32476498 DOI: 10.1080/13543784.2020.1777276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Rottembourg JB, Kpade F, Tebibel F, Dansaert A, Chenuc G. Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational study. BMC Nephrol 2013;14:243. [PMID: 24180578 DOI: 10.1186/1471-2369-14-243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
28 Wetmore JB, Li S, Yan H, Xu H, Peng Y, Sinsakul MV, Liu J, Gilbertson DT. Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. PLoS One 2018;13:e0203767. [PMID: 30256836 DOI: 10.1371/journal.pone.0203767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
29 Soni RK, Weisbord SD, Unruh ML. Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19:153-9. [PMID: 20051850 DOI: 10.1097/MNH.0b013e328335f939] [Cited by in Crossref: 83] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
30 Pérez-García R, Varas J, Cives A, Martín-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI; ORD group. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant 2018;33:690-9. [PMID: 29036505 DOI: 10.1093/ndt/gfx269] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
31 Veys N, Van Biesen W, Lameire N. INTERNAL MEDICINE, RENAL ANAEMIA, AND ERYTHROPOIESIS-STIMULATING AGENTS (ESAS). Acta Clinica Belgica 2014;62:396-407. [DOI: 10.1179/acb.2007.059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]